Intellectual Property Alert - Federal Circuit Upholds Abilify® (Aripiprazole) Composition Patent


In an opinion that referred to a Defendant’s obviousness case for a small-molecule drug as “a poster child for impermissible hindsight reasoning,” the Federal Circuit affirmed a decision of the District Court for the District of New Jersey that upheld the validity of U.S. Patent No. 5,006,528, which provides composition of matter protection for the antipsychotic agent Abilify® (aripiprazole).  The case, decided on May 7, 2012, is Otsuka Pharmaceutical Co., LTD. v. Sandoz, Inc., et al.  Read more ...